CD70 is a cell-surface antigen that is frequently overexpressed in multiple hematological and solid malignancies and generally absent from normal tissues.

PRO1160 is comprised of a human monoclonal antibody that selectively binds CD70, a novel cleavable hydrophilic linker, and a topoisomerase 1 inhibitor payload, exatecan.

PRO1160 displays a promising preclinical profile on PK, efficacy, and tolerability, supporting its further development for various cancers including renal cell carcinoma (RCC), nasopharyngeal carcinoma (NPC), and non-Hodgkin lymphoma (NHL).